Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.
Costanzo A, Russo F, Galluzzo M, Stingeni L, Scuderi R, Zichichi L, Papini M, Di Costanzo L, Conti A, Burlando M, Chiricozzi A, Gaiani FM, Mugheddu C, Musumeci ML, Gisondi P, Piaserico S, Dapavo P, Venturini M, Pagnanelli G, Amerio P, Potenza C, Peris K, Cantoresi F, Trevisini S, Loconsole F, Offidani A, Mercuri SR, Lora V, Prignano F, Bartezaghi M, Oliva G, Aloisi E, Orsenigo R. Costanzo A, et al. Among authors: burlando m. Acta Derm Venereol. 2021 Oct 21;101(10):adv00576. doi: 10.2340/00015555-3816. Acta Derm Venereol. 2021. PMID: 33903916 Free PMC article. Clinical Trial.
Condylomata Lata and Papular Rash of Secondary Syphilis.
Herzum A, Burlando M, Micalizzi C, Parodi A. Herzum A, et al. Among authors: burlando m. Actas Dermosifiliogr. 2023 May;114(5):T447. doi: 10.1016/j.ad.2023.04.006. Epub 2023 Apr 6. Actas Dermosifiliogr. 2023. PMID: 37030562 Free article. English, Spanish. No abstract available.
Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience.
Conti A, Peccerillo F, Amerio P, Balato A, Bardazzi F, Bianchi L, Burlando M, Cannavò SP, Chiricozzi A, Dapavo P, De Simone C, Fargnoli MC, Gambardella A, Gisondi P, Malagoli P, Malara G, Mugheddu C, Offidani AM, Piaserico S, Prignano F, Stingeni L, Pellacani G. Conti A, et al. Among authors: burlando m. Br J Dermatol. 2019 Jun;180(6):1547-1548. doi: 10.1111/bjd.17580. Epub 2019 Feb 21. Br J Dermatol. 2019. PMID: 30578668 No abstract available.
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study.
Papini M, Cusano F, Romanelli M, Burlando M, Stinco G, Girolomoni G, Peris K, Potenza C, Offidani A, Bartezaghi M, Aloisi E, Costanzo A; SUPREME study group. Papini M, et al. Among authors: burlando m. Br J Dermatol. 2019 Aug;181(2):413-414. doi: 10.1111/bjd.18013. Epub 2019 May 29. Br J Dermatol. 2019. PMID: 31001812 Clinical Trial. No abstract available.
141 results